Efficacy and safety of levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson’s disease: a Turkish single-centre experience
Objective: This study is aimed to investigate the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish movement disorder center.…Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy
Objective: To develop population pharmacokinetic (PK) models for levodopa (LD) and carbidopa (CD) following subcutaneous (SC) infusion, including adjunct oral LD/CD administration. Background: ND0612 is…Monitoring electrophysiological recordings in patients with LCIJ therapy
Objective: Levodopa carbidopa intestinal jel (LCIJ) treatment for advanced Parkinson’s disease patients is live-saving for the appropriate patients, however follow up of the patients has…Levodopa induced changes of tongue body movements during speech production
Objective: This study investigates the influence of levodopa (L-dopa) on tongue body movements during speaking. Background: Parkinson’s disease (PD) is a neurodegenerative disorder affecting non-motor…Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease
Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…Effectiveness of Carbidopa/Levodopa Enteral Suspension (CLES) in Advanced Parkinson’s Disease (APD) Patients with Moderate to Severe Fatigue: Sub-group Analysis from PROviDE study
Objective: To examine the effect of CLES at 12 months of follow-up in APD patients with moderate to severe fatigue. Background: Fatigue, one of the…Inhaled levodopa (LD) as a treatment for Parkinson’s disease (PD) patients in an emergency setting
Objective: To report on use of CVT-301 (inhaled LD) to treat PD patients with complicated OFF period symptoms who present to the emergency department (ED).…Nurse led intrajejunal levodopa pathway for a regional neurosciences centre
Objective: To evaluate the impact of introducing a nurse led advanced therapy service for patients referred for levodopa/carbidopa intestinal gel (LCIG). Background: Leeds Teaching Hospitals…CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks
Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 57
- Next Page »